Skip to content
10-Q

Quarterly Report

TVARDI THERAPEUTICS, INC. TVRD

0001104659-26-057528

← back to feed
Filed
May 8, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 5, 2026 9.38M sh
Shares Diluted Q1 2026 · Mar 31, 2026 9.38M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 2.58M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$5.86M
Operating Cash Flow restated Q1 2026 · Mar 31, 2025 −$7.69M
Short Term Investments Q1 2026 · Mar 31, 2026 $5.13M
Short Term Investments Q1 2026 · Dec 31, 2025 $10.08M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $19.85M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $20.73M
Stockholders Equity Q1 2026 · Mar 31, 2026 $14.51M
Stockholders Equity Q1 2026 · Dec 31, 2025 $20.95M
Stockholders Equity restated Q1 2026 · Mar 31, 2025 −$100.63M
Stockholders Equity restated Q1 2026 · Dec 31, 2024 −$91.13M
Current Liabilities Q1 2026 · Mar 31, 2026 $11.26M
Current Liabilities Q1 2026 · Dec 31, 2025 $11.04M
Total Liabilities Q1 2026 · Mar 31, 2026 $11.31M
Total Liabilities Q1 2026 · Dec 31, 2025 $11.13M
Current Assets Q1 2026 · Mar 31, 2026 $25.33M
Current Assets Q1 2026 · Dec 31, 2025 $31.54M
Total Assets Q1 2026 · Mar 31, 2026 $25.82M
Total Assets Q1 2026 · Dec 31, 2025 $32.07M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.73
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$3.72
Eps Basic Q1 2026 · Mar 31, 2026 −$0.73
Eps Basic restated Q1 2026 · Mar 31, 2025 −$3.72
Sga Expense Q1 2026 · Mar 31, 2026 $2.14M
Sga Expense restated Q1 2026 · Mar 31, 2025 $1.24M
Rd Expense Q1 2026 · Mar 31, 2026 $4.91M
Rd Expense restated Q1 2026 · Mar 31, 2025 $3.11M
Net Income Q1 2026 · Mar 31, 2026 −$6.8M
Net Income restated Q1 2026 · Mar 31, 2025 −$9.58M
Operating Income Q1 2026 · Mar 31, 2026 −$7.05M
Operating Income restated Q1 2026 · Mar 31, 2025 −$4.35M